Australia Non-Invasive Prenatal Testing Market Report 2025: NIPT Market to Expand to $83.3 Million by 2033 Amid Rising Genetic Awareness - ResearchAndMarkets.com

May 15, 2025 02:24 AM AEST | By Business Wire
 Australia Non-Invasive Prenatal Testing Market Report 2025: NIPT Market to Expand to $83.3 Million by 2033 Amid Rising Genetic Awareness - ResearchAndMarkets.com
Image source: Kalkine Media

DUBLIN--(BUSINESS WIRE)--The "Australia Non-Invasive Prenatal Testing Market 2025 - 2033" has been added to ResearchAndMarkets.com's offering.

The Australia Non-Invasive Prenatal Testing (NIPT) market, valued at USD 57.8 million in 2024, is expected to reach USD 83.3 million by 2033, expanding at a 4.1% CAGR from 2025 to 2033.

The report's scope encompasses a comprehensive research methodology, insights into market determinants, historical market growth from 2018 to 2024, and future projections. It evaluates the number of NIPT tests conducted with forecasts for eight years, offering a complete market potential and opportunity assessment.

The expansion of the Australian NIPT market is driven by several factors. A heightened awareness among healthcare providers and parents regarding early detection of genetic abnormalities has led to increased demand for NIPT. Initiatives aimed at educating these groups and the rise of hereditary genetic disorders further fuel this demand.

Technological innovations in genomic sequencing have enhanced the accessibility and affordability of NIPT, with more healthcare facilities adopting these advanced technologies, thereby improving reliability and efficiency. Government support has also played a crucial role. Regulatory frameworks designed to promote the adoption of NIPT have improved public trust and incentivized service providers to integrate these tests into their offerings, thus encouraging market growth.

The market report offers an exhaustive examination of the Australia NIPT market, including the latest industry data, historical market size from 2018-2024, and forecasts extending to 2033. It delves into industry situations, market demands, test volumes, revenues, and forecasts through 2033. The report also includes a comparative test analysis by companies, exploring reimbursement patterns and offering insights into the regulatory landscape in Australia.

Detailed analysis of trends such as collaboration deals, partnerships, mergers and acquisitions, venture capital investments, and licensing agreements are covered extensively. Additionally, the report includes a SWOT analysis, evaluating market drivers and challenges within the Australian context. Leading market players, assessed on business outlook and developments, are also profiled.

Prominent players in the Australia NIPT market include:

  • Healius Limited
  • Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Novacyt
  • BGI Genomics
  • Natera, Inc.
  • Monash IVF Group
  • Virtus Health
  • Sonic Healthcare Limited
  • Victorian Clinical Genetics Services Limited

Key Attributes:

Report Attribute Details
No. of Pages 70
Forecast Period 2024 - 2033
Estimated Market Value (USD) in 2024 $57.8 Million
Forecasted Market Value (USD) by 2033 $83.3 Million
Compound Annual Growth Rate 4.1%
Regions Covered Australia

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Australia Non-Invasive Prenatal Testing Volume and Forecast (2018 - 2033)

5. Australia Non-Invasive Prenatal Testing Market Size and Forecast (2018 - 2033)

6. Australia Non-Invasive Prenatal Testing Market Growth Drivers and Challenges

7. Non-Invasive Prenatal Testing Comparative Analysis

8. Reimbursement Environment of the Australia Non-Invasive Prenatal Testing Market

9. Regulation Framework of the Australia Non-Invasive Prenatal Testing Market

10. Major Deals and Agreements in the Non-Invasive Prenatal Testing Market

11. SWOT Analysis

12. Key Companies Analysis

  • BGI Genomics
  • F. Hoffmann-La Roche Ltd
  • Healius Limited
  • Illumina, Inc.
  • Monash IVF Group
  • Natera, Inc.
  • Novacyt
  • Sonic Healthcare Limited
  • Victorian Clinical Genetics Services Limited
  • Virtus Health

For more information about this report visit https://www.researchandmarkets.com/r/cdedbw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.